| This strain is only available for Australian and New Zealand researchers
NSG mice combine the features of the NOD/ShiLtJ background, the severe combined immune deficiency mutation (scid) and IL2 receptor gamma chain deficiency. As a result, these NSG mice lack mature T cells, B cells, or functional NK cells, and are deficient in cytokine signaling, leading to better engraftment of human hematopoietic stem cells and peripheral-blood mononuclear cells than any other published mouse strain. Recent publications have demonstrated this strain’s outstanding utility in the studies of islet transplantation, hematopoietic stem cells and cancer stem cells.
Like its parental strain, NOD/ShiLtJ (Stock No. 001976), NSG mice exhibit a progressive hearing loss that is already severe by three months of age.
Housed in isolators at the ARC.
Due to their level of immunodeficiency NSG mice need to be maintained in a ‘maximum barrier’. A description of maximum barrier conditions and practices is available on the Jax website.
Further detailed information is also available at: http://jaxmice.jax.org/strain/005557.html
These mice are sold subject to The Jackson Laboratory’s Conditions of Use and also the Australian Patent Number (2004268530). Information regarding conditions of use is available at: Jax General Terms and Conditions.
|
